SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

LUNRs sharp rally is being tied by traders to anticipated NASA CLPS 2.0 awards and related lunar-program updates, with some claiming the company is a selected vendor while others question whether an award announcement is confirmed. Bulls are celebrating the move and speculating about short covering, while skeptics warn it could fade; the upcoming earnings report is also in focus.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads clinical pipeline is drawing attention, particularly strong Phase 3 plozasiran results in severe hypertriglyceridemia and early ARO-MAPT evidence of tau reduction after subcutaneous dosing. Bulls see validation of the broader RNAi platform, while others focus on the stocks muted or weakening reaction and note that MAPTs biomarker results do not yet establish clinical benefit.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires Q3 results are drawing attention as weaker operating performance, particularly in insurance underwriting, contrasts with a sharp increase in share repurchases. Traders are split between concern over the earnings softness and reduced stock buying, and support for the buybacks and Berkshires cash-rich balance sheet.

American Express Co. engages in the provision of card-issuing, merchant-acquiring, and card network businesses. Its products and services include credit cards, business credit cards, corporate programs, gift cards, savings accounts and CDs, and the American Express App. It operates through the following segments: the United States Consumer Services (USCS), Commercial Services (CS), International Card Services (ICS), Global Merchant and Network Services (GMNS), and Corporate and Other. The USCS segment includes proprietary consumer cards and provides services to United States consumers. The CS segment offers corporate and small business cards and provides services to United States businesses. The ICS segment provides consumers, small businesses, and corporate cards outside the United States. The GMNS segment is involved in operating a global payments network that processes and settles card transactions, acquires merchants, and provides multi-channel marketing programs and capabilities, services and data analytics. The Corporate and Other segment covers corporate functions and certain other businesses and operations. It also operates through the following geographical segments: United States, EMEA, APAC, LACC, and Other. The EMEA segment represents Europe, the Middle East, and Africa. The APAC segment refers to Asia Pacific, Australia, and New Zealand. The LACC segment focuses on Latin America, Canada, and the Caribbean. The Other segment includes net costs which are not directly allocated to specific geographic regions. The company was founded by Henry Wells, William G. Fargo, and John Warren Butterfield on March 28, 1850 and is headquartered in New York, NY.

American Express Co.

American Express is drawing attention over reported stock sales by CEO Stephen Squeri and another senior executive, with traders debating whether the insider selling signals concern or is routine. Speculation about dark-pool activity is also circulating, while other traders remain bullish on AXPs valuation and long-term prospects.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

FDA accelerated approval of Replimunes melanoma therapy Tudriqev has driven a sharp rebound and talk of a short squeeze, with bulls focused on the commercial launch and institutional demand. Bears counter that adoption, efficacy and future dilution remain risks.

Eaton Corp. Plc is a power management company, which provides energy-efficient solutions for electrical, hydraulic, and mechanical power. It operates through the following segments: Electrical Americas and Electrical Global; Aerospace, Vehicle, and eMobility. The Electrical Americas and Electrical Global segments engage in sales contracts for electrical components, industrial components, power distribution and assemblies, residential products, single and three phase power quality, wiring devices, circuit protection, utility power distribution, power reliability equipment, and service. The Aerospace segment supplies aerospace fuel, hydraulics, and pneumatic systems for commercial and military use. The Vehicle segment deals with the design, manufacture, marketing, and supply of drivetrain and powertrain systems and critical components that reduce emissions and improve fuel economy, stability, performance and safety of cars, light trucks and commercial vehicles. The eMobility segment designs, manufactures, markets, and supplies electrical and electronic components and systems that improve the power management and performance of both on-road and off-road vehicles. The company was founded in 1911 and is headquartered in Dublin, Ireland.

Eaton Corporation plc

Eatons strong third-quarter results and higher full-year guidance, alongside accelerating electrical orders and backlog tied to data-center power demand, are driving attention. Many traders view the report as confirmation of the AI infrastructure opportunity, while others question whether backlogs are secure if projects face delays and whether the stocks valuation already reflects much of that growth.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Concern that Johnson & Johnsons bleximenib could challenge Kuras ziftomenib in frontline AML is driving debate, with traders questioning whether differences in prior venetoclax exposure make the competitor data less comparable. Some view the selloff as an overreaction and point to KOMZIFTIs commercial progress and upcoming company updates, while others see a genuine competitive threat.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention amid a persistent selloff and frustration that tokenization and institutional-adoption developments, including the discussed DTCC plans, have not translated into lasting price strength. Bears blame ongoing selling and weak token economics, while bulls continue to buy dips and cite Stellars real-world-asset and payments activity as a longer-term case.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,505.961324. The last known price of Zebec Network is 0.00185282 USD and is down -2.31 over the last 24 hours. It is currently trading on 133 active market(s) with $11,016,611.66 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Zebecs payroll and payments expansionincluding community discussion of MoneyGram/Stellar, Germany, and Robinhood Chain developmentsis driving attention as holders look for real-world adoption to translate into ZBCN demand. Bullish traders are accumulating on the partnership and buyback thesis, while skeptics point to weak price action and question whether business growth is creating meaningful token value; rumored Ripple or BlackRock links remain speculation.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons stronger-than-expected quarterly results, with refining strength amid tight diesel markets, are driving attention. Traders are weighing the earnings and cash-generation story against questions about whether elevated refining margins and oil-market support will last.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences Jazz Pharmaceuticals to Participate in Upcoming Investor ConferencesPR NewswireDUBLIN, Nov. 3, 2026 DUBLIN, Nov. 3, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will...

JAZZ Q3 Earnings & Sales Beat Estimates, Raises '26 Sales View

Jazz Pharmaceuticals beat Q3 2026 revenue and earnings estimates, driven by oncology and rare sleep growth, and raises its full-year sales outlook.

Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of +5.13% and +2.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results

Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results Jazz Pharmaceuticals Announces Third Quarter 2026 Financial ResultsPR NewswireDUBLIN, Nov. 2, 2026 Broad commercial execution drives record quarterly revenues of $1.2 billion (+10% YoY) Company raises full year 2026 total revenue...

Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026

Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026PR NewswireDUBLIN, Nov. 2, 2026 Presentations showcase Phase 3 ACTION trial progress and continued development of novel therapies for rare...

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal...

Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?

AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.

• Reported GAAP EPS of -$3.88 down -147.72% YoY
• Reported revenue of $1.24B up 10.38% YoY
• Jazz Pharmaceuticals expects total revenues in 2026 to increase compared to 2025; cost of product sales to be in line, SG&A to decrease, and R&D expenses to increase compared to 2025.

Jazz Pharmaceuticals posted a -$483.4M quarterly loss with $754.2M acquired IPR&D expense; Xywav dependence and oxybate competition persist, and Praxis litigation could restrict ABS-1230 development.

Jazz Pharmaceuticals reported Xywav growth and approximately 17,550 active patients, expanded oncology through Ziihera's first-line GEA launch, and disclosed sustained three-year survival benefit in Ziihera-containing combinations.

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Zanidatamab, marketed as Ziihera, was originally developed by Zymeworks before being licensed by Jazz.</li><li>The FDA decision triggered a $250 million milestone payment from Jazz to Zymeworks.</li><li>The approval was based on the Phase 3 HERIZON-GEA-01 study.</li></ul>Shares of Jazz Pharmaceuticals (JAZZ) gained around 4% on Tuesday to hit an all-time high after the U.S. Food and Drug Administration approved two treatments as initial therapy for adults with advanced HER2-positive gastroesophageal adenocarcinoma (GE).The treatments are based on Ziihera, a cancer medicine developed and marketed by Jazz. The approval covers Ziihera with chemotherapy, as well as Ziihera with BeOne Medicines’ (ONC) Tevimbra immunotherapy.Gastroesophageal adenocarcinoma includes cancers of the stomach and the esophagus. About 20% of patients have a protein called HER2, which helps the cancer cells spread. Ziihera blocks the protein.<h2 class="st-heading-2">ZYME To Receive $250M</h2>Zanidatamab, marketed as Ziihera, was originally developed by Zymeworks (ZYME), before being licensed by Jazz. The FDA decision triggered a $250 million <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.zymeworks.com/node/13736/ixbrl-viewer">milestone payment</a> from Jazz to Zymeworks. Zymeworks is also eligible for royalties ranging from 10% to 20% on Ziihera sales.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/ONC">ONC stock</a> was up 2% while&nbsp;<a href="https://stocktwits.com/symbol/ZYME">ZYME shares</a> fell 7%.<h2 class="st-heading-2">Phase 3 Trial Shows Longer Survival</h2>The approval was based on the Phase 3 HERIZON-GEA-01 study. Both Ziihera combinations reduced the risk of disease progression by 35% compared with the combination of Trastuzumab and chemotherapy. Median progression-free survival was 12.4 months versus 8.1 months in the comparison group.The combinations also reduced the risk of death by 28%. Patients receiving the combination had median overall survival of 26.4 months, compared with 19.2 months for those receiving trastuzumab and chemotherapy.“Today’s approval gives people diagnosed with HER2+ GEA a much-needed new treatment option and more choice in how their cancer is treated," said Martha Raymond, CEO and founder of GI Cancers Alliance.The FDA decision triggered a $250 million milestone payment from Jazz to Zymeworks. Zymeworks is also eligible for royalties ranging from 10% to 20% on Jazz’s Ziihera sales.Retail sentiment surrounding&nbsp;<a href="https://stocktwits.com/symbol/JAZZ">JAZZ</a> on Stocktwits remained ‘bullish’ over the past 24 hours, while the sentiment flipped to ‘bullish’ from ‘bearish’ for ONC. ZYME sentiment trended in the ‘extremely bullish’ territory over the past 24 hours, despite the intraday decline.JAZZ shares gained 51% so far this year, ONC stock has grown 22%, while ZYME stock has declined around 2%.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/lululemon-may-cut-annual-earnings-outlook-amid-weak-us-china-sales-warns-ubs/cZYktdnRJo2">&nbsp;Lululemon May Cut Annual Earnings Outlook Amid Weak US, China Sales, Warns UBS</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SLS stock has rocketed 636% over the past year. (Photo credit: Getty Images)

The FDA approved Jazz Pharma’s Ziihera with chemotherapy, with or without BeOne’s Tevimbra, as an initial treatment for advanced HER2-positive gastroesophageal cancer.

BeOne Medicines Ltd - ADR

Zymeworks Inc

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$6.95	--	--	N/A
Q3 '26	-$4.05	-$3.88	4.09%	BEAT
Q2 '26	$6.18	$5.71	-7.53%	MISSED
Q1 '26	$4.66	$6.34	36.17%	BEAT
Q4 '25	$6.52	$6.64	1.88%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

JAZZ Earnings

Latest Earnings Results: Q3 '26

Historical Earnings